Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Rezafungin acetate by Napp Pharmaceuticals for Aspergillosis: Likelihood of Approval
Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Aspergillosis. According to GlobalData, Phase...
Data Insights
Rezafungin acetate by Napp Pharmaceuticals for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia): Likelihood of Approval
Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)....